Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.66 USD | +6.22% | +8.87% | -2.93% |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
Financials (USD)
Sales 2024 * | 179M | Sales 2025 * | 202M | Capitalization | 274M |
---|---|---|---|---|---|
Net income 2024 * | -18M | Net income 2025 * | - | EV / Sales 2024 * | 1.53 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.36 x |
P/E ratio 2024 * |
-15.2
x | P/E ratio 2025 * |
-470
x | Employees | 427 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.22% |
Latest transcript on AxoGen, Inc.
1 day | +2.62% | ||
1 week | +1.13% | ||
Current month | -2.18% | ||
1 month | -5.43% | ||
3 months | -41.24% | ||
6 months | +4.85% | ||
Current year | -8.20% |
Managers | Title | Age | Since |
---|---|---|---|
Karen Zaderej
CEO | Chief Executive Officer | 62 | 06-04-30 |
Nir Naor
DFI | Director of Finance/CFO | 49 | Dec. 05 |
Marc Began
CMP | Compliance Officer | 57 | 23-03-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Thomas
BRD | Director/Board Member | 68 | 20-09-29 |
Director/Board Member | 63 | 16-08-31 | |
John Johnson
BRD | Director/Board Member | 66 | 21-07-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 6.63 | +5.74% | 257 224 |
24-05-24 | 6.27 | +2.62% | 235,047 |
24-05-23 | 6.11 | -1.45% | 516,883 |
24-05-22 | 6.2 | +1.81% | 262,505 |
24-05-21 | 6.09 | -1.77% | 163,210 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.20% | 274M | |
+10.03% | 223B | |
+13.59% | 195B | |
+20.01% | 144B | |
+30.83% | 111B | |
+3.00% | 65.19B | |
+15.38% | 53.02B | |
+3.64% | 50.28B | |
+8.37% | 44.15B | |
+3.27% | 36.45B |
- Stock Market
- Equities
- AXGN Stock